TIDES: Oligonucleotide & Peptide Therapeutics

May 20-23, 2019
Manchester Grand Hyatt
San Diego, CA

THE LARGEST MEETING TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE PRODUCTS FROM EARLY DISCOVERY TO LATE-STAGE DEVELOPMENT & COMMERCIALIZATION

Featuring Industry Experts to Help You Fast-Track Product Development

**Rare Diseases and RNA-Targeted Medicines**
- Sarah Boyce
  - President, Akcea Therapeutics

**RNAi Therapeutics: Onpattro and Beyond**
- Kevin Fitzgerald, Ph.D.
  - Senior Vice President and Head of Research, Alnylam Pharmaceuticals

**Antisense Technology: Today and Tomorrow**
- Stanley Crooke, M.D., Ph.D.
  - Chairman of the Board and Chief Executive Officer, Ionis Pharmaceuticals

**A Platform for In-solution Enrichment from Large Libraries to Identify Peptide Inhibitors of Protein-Protein Interactions**
- Bradley Pentelute, Ph.D.
  - Professor, Chemistry, Massachusetts Institute of Technology

www.TIDESevent.com
@TIDES365  #TIDES365
TIDES: Oligonucleotide & Peptide Therapeutics

THE INDUSTRY’S FLAGSHIP MEETING FOR OLIGONUCLEOTIDE AND PEPTIDE SCIENCE, TECHNOLOGY AND NETWORKING

SCIENCE

Accelerate your pipeline of oligonucleotide and peptide therapeutics to market by applying best practices and lessons learned from 125+ case studies and new data presentations from global industry leaders working across the entire spectrum of development and production.

TECHNOLOGY

Bring your product to market by meeting 90+ leading product and service providers showcasing live technology demonstrations in our exhibit hall.

NETWORKING

Connect with 1000+ scientists and executives from 30 countries focused in oligonucleotide and peptide development and production during luncheons, cocktail receptions and networking breaks. Networking has never been easier with the included TIDES app that allows you to view the attendee list and schedule meetings before, during and after the event.

"TIDES is the premier venue to actually network with the peptide community. It attracts the research community up to the clinical community — it covers the entire spectrum of peptide science."
- Dr. Alex Fässler, Bachem AG

"TIDES is a ‘must-go’ conference for scientists working in the peptide/oligonucleotide area"
- George Wang, Analytical Chemist, Bristol-Myers Squibb

"Definitely the best meeting in the US for companies developing peptide therapeutics"
- Rodney Lax, Ph.D., Senior Director, PolyPeptide Group

For up-to-date program information and new abstracts, visit: www.TIDESevent.com
# Agenda at a Glance

**Monday, May 20, 2019 • Pre-Conference Workshops**

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop #1: The State of the Art in mRNA Delivery (Room: Solana Beach)</th>
<th>Workshop #2: Oligonucleotide Drug Development at Warp Speed: Managing CMC Operations to Support Accelerated Clinical Development (Room: Mission Beach)</th>
<th>Workshop #3: Potential Green Chemistry Solutions for Peptide Manufacturing (Room: Ocean Beach)</th>
<th>Workshop #4: Accelerating Peptides to IND: Moving to the Clinic, CMC and Beyond (Room: Promenade)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>12:00 pm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>5:00 pm</td>
<td>Workshop #5: Peptide Aggregation – Challenges, Effects, and Solutions (Room: Ocean Beach)</td>
<td>Workshop #6: The Path to a Successful Oligonucleotide IND/IMPD Submission: Regulatory, Nonclinical and CMC Perspectives (Room: Mission Beach)</td>
<td>Workshop #7: Evolving Regulatory CMC Requirements for Peptides (Room: Promenade)</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>10:45 am</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tuesday, May 21, 2019 • Main Conference**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td><strong>KEYNOTE SESSION (Room: Seaport ABC):</strong></td>
<td></td>
</tr>
<tr>
<td>8:20 am</td>
<td>12:15 pm</td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td>1:25 pm</td>
<td></td>
</tr>
<tr>
<td>10:00 am</td>
<td>3:25 pm</td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td>4:25 pm</td>
<td></td>
</tr>
<tr>
<td>12:00 pm</td>
<td>5:25 pm</td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>6:25 pm</td>
<td></td>
</tr>
</tbody>
</table>

**Wednesday, May 22, 2019 • Main Conference**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 am</td>
<td><strong>Exhibit Hall &amp; Poster Viewing Hours: 10:00 am – 6:45 pm</strong></td>
<td></td>
</tr>
<tr>
<td>8:25 am</td>
<td>10:00 am</td>
<td></td>
</tr>
<tr>
<td>10:45 am</td>
<td>12:15 pm</td>
<td></td>
</tr>
<tr>
<td>12:00 pm</td>
<td>2:15 pm</td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>3:15 pm</td>
<td></td>
</tr>
</tbody>
</table>

**Thursday, May 23, 2019 • Main Conference**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 am</td>
<td><strong>Exhibit Hall &amp; Poster Viewing Hours: 10:00 am-2:00 pm</strong></td>
<td></td>
</tr>
<tr>
<td>8:25 am</td>
<td>10:00 am</td>
<td></td>
</tr>
<tr>
<td>10:45 am</td>
<td>12:15 pm</td>
<td></td>
</tr>
<tr>
<td>12:00 pm</td>
<td>2:15 pm</td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>3:15 pm</td>
<td></td>
</tr>
</tbody>
</table>
MONDAY, MAY 20, 2019 • CONCURRENT MORNING HALF-DAY WORKSHOPS

**Workshop #1:**
The State of the Art in mRNA Delivery
Morning Half-Day Workshop • 8:00am-12:00pm

- **Room:** Solana Beach AB

  8:00  Workshop Moderator’s Opening Remarks
  Örn Almarsson, Ph.D., Head of Formulations, Moderna Therapeutics

  8:15  LUNAR®: Enabling mRNA Therapeutics and Vaccines
  Pad Chivukula, Ph.D., CSO and COO, Arcturus Therapeutics

  8:45  Safe Delivery of Nucleic Acid Cargoes Using Anionic Carriers
  Steffen Panzner, Ph.D., CEO, Germany

  9:15  Chemical Design of Synthetic Carriers for CRISPR/Cas Gene Editing and mRNA-mediated Protein Replacement Therapy
  Daniel Siegwart, Ph.D., Associate Professor, Department of Biochemistry, UT Southwestern Medical Center

  9:45  Networking Refreshment Break

  10:15  Advancing the Delivery of LNP-encapsulated mRNA Therapeutics
  Frank DeRosa, Ph.D., Senior Vice President, R&D, Translate Bio

  10:45  Development of Nucleic Acid Delivery Platforms; a pan-RNA approach
  James Heyes, Ph.D., SVF Technology Development, Genvance Sciences, Canada

  11:15  Delivering mRNA Products from Discovery through Development - Opportunities and Challenges
  Hari Pujar, Head of Technical Development, Moderna Therapeutics

  11:45  Concluding Remarks and Discussion

  12:00  Close of Workshop

**Workshop #2:**
Oligonucleotide Drug Development at Warp Speed: Managing CMC Operations to Support Accelerated Clinical Development
Morning Half-Day Workshop • 8:00am-12:00pm

- **Room:** Mission Beach

  8:00  Workshop Co-Moderators’ Opening Remarks
  G. Susan Srivatsa, Ph.D., President, ElixinPharma
  Fran Wincott, Ph.D., Wincott & Associates, LLC

  8:20  Points to Consider with US and EU Expedited Regulatory Pathways
  Paul Manley, President and Principal Consultant, Orvieto Consulting

  8:50  From Target to Patient; Options for Oligonucleotides as Personalized Medicines
  Chantal Reed, Ph.D., Vice President, Brain Hz Consulting, Inc.

  9:20  Use of Prior Knowledge to Establish Enhanced Flexible Platform-based Control Strategies
  Zhijie Sui, Ph.D., Senior Scientist, Technical Development, Biogen

  9:50  Networking Refreshment Break

  10:20  Process Validation Approaches for Accelerated Programs
  Lisa deCardenas, Regulatory Program Manager, Genentech

  10:50  Supporting Accelerated Development - Stability Approaches
  Eric McKinney, Director, Stability and Specifications, Alnylam Pharmaceuticals

  11:20  Panel Discussion with Workshop Speakers

  12:00  Close of Workshop

**Workshop #3:**
Potential Green Chemistry Solutions for Peptide Manufacturing
Morning Half-Day Workshop • 8:00am-12:00pm

- **Room:** Ocean Beach

  8:00  Workshop Moderator’s Opening Remarks
  Trishul Shah, Director, Business Development, North America, PolyPeptide

  8:15  Solid-Phase Peptide Synthesis: Being Greener, Being Better
  Fernando Albericio, Ph.D., Professor, Organic Chemistry, University of Barcelona

  9:00  Evolved Enzymes for Commercial Chemical Synthesis Pathways
  Christina Boville, Ph.D., Resnick Prize Postdoctoral Scholar, Fmcs Arnold Lab, California Institute of Technology

  9:45  Networking Refreshment Break

  10:15  Convergent Peptide Synthesis in Flow: Preferred Regulatory Strategies for Commercial Peptide Manufacture
  Michael Kopach, Ph.D., Senior Research Advisor, Eli Lilly and Company

  11:00  Perspectives on Green Chemistry
  Jon Holbech Rasmussen, Ph.D., Director, Global Development, PolyPeptide Group, Sweden

  11:45  Concluding Remarks and Discussion

  12:00  Close of Workshop

**Workshop #4:**
Accelerating Peptides to IND: Moving to the Clinic, CMC and Beyond
Morning Half-Day Workshop • 8:00am-12:00pm

- **Room:** Promenade

  8:00  Workshop Moderator’s Opening Remarks
  Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahaest

  8:15  Analytical Methods, Pre-formulation, and Formulation for Early Phase Development
  Christopher Rhodes, Ph.D., President and CEO, Drug Delivery Experts

  9:00  IND-enabling, Nonclinical Safety Studies for Peptides: Pharmacokinetics, Bioanalysis and Toxicology
  Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahaest

  9:45  Networking Refreshment Break

  10:15  Peptide CMC Approaches for a Fast and Successful IND Filing
  Mmouni Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland

  11:00  Speaker TBA

  11:45  Concluding Remarks and Discussion

  12:00  Close of Workshop

12:00-1:00  Spotlight Presentation Luncheons

For up-to-date program information and new abstracts, visit: [www.TIDESevent.com](http://www.TIDESevent.com)
Tuesday, May 21, 2019 • KEYNOTE SESSION

7:30 Registration (Grand Foyer) and Breakfast (Seaport Foyer)

8:20 Chairperson’s Remarks
Firoz D. Antia, Ph.D., Director, Antisense Oligonucleotide Process Development and Manufacturing, Biogen

8:30 Antisense Technology: Today and Tomorrow
Stanley Crooke, M.D., Ph.D.
Chairman of the Board and Chief Executive Officer, Ionis Pharmaceuticals

9:30 RNAi Therapeutics: Onpattro and Beyond
Kevin Fitzgerald, Ph.D.
Senior Vice President and Head of Research, Alnylam Pharmaceuticals

10:15 Networking Refreshment Break

10:45 A Platform for In-solution Enrichment from Large Libraries to Identify Peptide Inhibitors of Protein-Protein Interactions
Bradley Pentelute, Ph.D.
Professor, Chemistry, Massachusetts Institute of Technology

11:30 Quality of Life – It’s Not Just a Numbers Game!
Sarah Boyce
President, Akcea Therapeutics

12:15-1:25 SPOTLIGHT PRESENTATION LUNCHEONS

(Room: Harbor D)
Track Record of Oligonucleotide and Peptide Manufacturing in Large Scale by Solution Phase Approach AJIPHASE®.
Daisuke Takahashi, Ph.D., Senior Principal Researcher, Research Institute for Bioscience Products & Fine Chemicals,
AJI Bio Pharma Services, Japan

(Room: Harbor E)
Lipid Nanoparticles – From Benchtop to Clinic: A CDMO Perspective
Di L. Bush, Ph.D., Formulations Director, Avanti Polar Lipids

(Room: Harbor F)
Selecting an Asian CMO Partner for Therapeutic Oligonucleotide Manufacturing
J.O. Adams, Head of Research, Ribo Biologics Co. Ltd., China

(Room: Harbor G)
Development of Synthetic Self-Replicating RNA Platforms for Oncology Vaccines and Therapeutics
Anton McCaffrey, Ph.D., Senior Director of Emerging Science and Innovation, TriLink BioTechnologies
Nathaniel Wang, Ph.D., Head of R&D, RNA Medicines, Synthetic Genomics, Inc.

For up-to-date program information and new abstracts, visit: www.TIDSevent.com
The Road to Personalized Medicines and Individualized Therapies

1:25 Chairperson’s Remarks
Trishul Shah, Director, Business Development, North America, PolyPeptide

1:30 Using Artificial Intelligence to Accelerate Drug Development and Precision Medicine
Brendan Frey, Ph.D., Founder and CEO, Deep Genomics

2:00 Parameters for Accelerated Development of Antisense Oligonucleotides as Personalized Medicine
Timothy Yu, M.D., Ph.D., Attending Physician, Division of Genetics and Genomics, Boston Children’s Hospital and Assistant Professor in Pediatrics, Harvard Medical School

2:30 Development of Neoantigen-Based Personalized Cancer Vaccine, NEO-PV-01
Jesse Z. Dong, Ph.D., Vice President, Peptide Chemistry, Neon Therapeutics

3:00 Grand Opening of Poster and Exhibit Hall and Networking Refreshment Break

3:45 mRNA as a Platform Technology Ideally Suited for Individualized Therapeutics
Andreas Kuhn, Ph.D., Vice President RNA Biochemistry & Manufacturing, BioNTech RNA Pharmaceuticals GmbH, Germany

4:15 Manufacturing NeoAntigen Peptides: Requirements and Pragmatism
Trishul Shah, Director, Business Development, North America, PolyPeptide

4:45 PANEL DISCUSSION WITH SESSION SPEAKERS: Personalized Medicine and Individualized Therapies
Moderator:
Trishul Shah, Director, Business Development, North America, PolyPeptide

5:15-6:45 Networking Reception in the Poster and Exhibit Hall
Join us for a Japanese inspired evening in the TIDES Exhibit Hall. Our food selections include a Ramen Noodle Bar, fortune cookies and origami decor!

Musical entertainment featuring Japanese American koto performer Reiko Obata. Ms. Obata is based in San Diego, California and will perform traditional and contemporary Japanese koto music.

Sponsored by: Ribobio
Cost Efficient Peptide Purification via ZEOsphere DRP Mixed-Mode Chromatography
(Room: Balboa ABC)
Timothy O’Mara, Sales Manager, Tocho Chemicals America

Lessons Learned from Liposomal Products and Processes – Chemistry, Manufacturing and Controls
(Room: Seaport BC)
Andreas Wagner, Ph.D., Head of Liposome Technology, Polyumun Scientific GmbH, Austria

Preclinical and Clinical Development of Oligonucleotide Therapeutics: Covering the Value Chain from Lead ID to Phase 1 Supply
(Room: Seaport A)
Hans-Peter Vornlocher, Ph.D., Managing Director Research, LGC Axolabs, Switzerland
Jürgen Mueller, Ph.D., Commercial and Strategic Development Director, LGC Axolabs

8:25 Chairwoman’s Remarks
Shuling Guo, Ph.D., Vice President, Antisense Drug Discovery, Ionis Pharmaceuticals

Chairman’s Remarks
Doug Brooks, Ph.D., Consultant, Matapal Pharma Consulting Services

Chairs Remarks
Waleed Danho, Ph.D., Consultant, Danho & Associates

Chairman’s Remarks
Alex Fässler, Ph.D., Bachem Holding AG, Switzerland

8:30 Human Genetics Moves from Clinic to Bench and Back: Develop Antisense Therapies for Inherited Diseases
Shuling Guo, Ph.D., Vice President, Antisense Drug Discovery, Ionis Pharmaceuticals

Industrial Scale Manufacture of 2-cyanoethyl-N,N,N’,N’-tetraisopropylphosphoramidite (Phos reagent)
Peter Thornton, Ph.D., Scientist, Solvay Solutions, United Kingdom

Genetically Encoded Selection of Novel Cyclic and Bicyclic Architectures
Ralmir Derda, Ph.D., Associate Professor, Department of Chemistry, University of Alberta, Canada

CMC Development Concept for Synthetic Peptides
Tanja Huth, Ph.D., Group Leader QA/RA Project Management, Bachem AG, Switzerland

9:00 Targeted Delivery of Oligonucleotides to Muscle with Antibody Oligo Conjugates
Arthur A. Levin, EVP Research and Development, Avidity Biosciences

Increasing Yields and Reducing Waste in Oligonucleotides Manufacture
Anna Watson, Senior Scientist (Process Engineer), Pharmaceutical Technology and Development, AstraZeneca, United Kingdom

Chemoenzymatic Synthesis of Macrocycles
David Craik, Ph.D., Professor of Biomolecular Structure, Institute for Molecular Biology, University of Queensland, Australia

Supply Chain and CMC Considerations during Development of Lumicell’s Cleaveable PEGylated Peptide-DrugConjugate for Fluorescence Guided Surgery
Daniel Harris, Ph.D., Director of Drug Manufacturing, Lumicell

9:30 Development of microRNA Therapeutics
Aimee L. Jackson, Ph.D., Vice President of Research, miSpagen Therapeutics


The Power of Isoacyl Chemistry: Its Application to Insulin and Glucagon
Fa Liu, Ph.D., Director of Discovery Chemistry, Novo Nordisk Research Center Seattle

APL-2 Drug Substance: Strategic Dual-sourcing of a PEGylated Peptide during Late Stage Clinical Development
Najib Maslouh, Vice President of Manufacturing and Technical Operations, Apellis Pharmaceuticals

10:00 Networking Refreshment Break in Poster and Exhibit Hall

10:45 Overcoming the Hurdle of Subcutaneous Delivery of mRNA in LNP to Enable Treatment of Chronic Diseases
Shalini Andersson, Ph.D., Senior Director and Head of New Therapeutic Modalities, AstraZeneca, Sweden

Enzyme Catalysed Assembly of Oligonucleotides
David Tew, Project Leader and GSK Senior Fellow, Advanced Manufacturing Technology, GlaxoSmithKline, United Kingdom

An Appropriate Screening Funnel at An Early Stage of Peptide Discovery is Key to Success: An Overview
Stefanitsa Colarusso, Senior Research Scientist, Peptide Chemistry, IRBM Science Park SPA, Italy

Introducing Green and Sustainable Chemistry in Liquid Phase Peptide Manufacturing Processes
El Djouhar Rekaï, Ph.D., Head of Development & Manufacturing Processes, PolyPeptide Group, Belgium

11:15 Small Activating RNAs – An Innovative Platform for Gene Activation
David Blakey, Ph.D., Chief Scientific Officer, MINA Therapeutics, United Kingdom

Applications of Hydrophilic Interaction Chromatography (HILIC) to Oligonucleotides
Zach Parsons, Ph.D., Research Scientist II, Aveca

Epitope Targeted Protein Catalyzed Capture Agents
Heather Agnew, Ph.D., Vice President R&D Operations, Indi Molecular

Building Enzymatically Degradable Tissue Scaffolds with Thiol-one Photo-click Polymer Chemistry: Development of Peptide Linkers for Biological Functionality, Chemical Reactivity, and Manufacturing Stability
Peter Marinier, Ph.D., Director of Wound Healing, Mosaic Biosciences

PANEL DISCUSSION: Optimizing Lipid Nanoparticles (LNPs) for Liver Delivery of CRISPR/Cas9
Panel Discussion Moderator:
Mannohan Singh, Ph.D., Vice President, Pharmaceutical Sciences and Delivery Technologies, Beam Therapeutics

Panelists:
Rubina Parmar, Ph.D., Director, Chemistry, Intella Therapeutics
Andy Geall, Ph.D., Vice President of Formulations, Analytics and Chemistry, Avity Biosciences
Samuel Clarke, Ph.D., Vice President of Formulations and Delivery, Precision NanoSystems, Canada

11:45 Speaker TBA

Purge-based Risk Assessment for Solvent and Small Molecule Impurities Generated during Oligonucleotide Synthesis
Robert Gonke, Ph.D., Senior Principal Scientist, Technical Development, Biothera
Ben Andrews, Ph.D., Scientific Investigator, API Chemistry, GlaxoSmithKline, United Kingdom

Challenges and Emerging Approaches in Peptide Phage Display and Its Application in Targeting Stem Cell Receptors
Rami Hannoush, Ph.D., Principal Scientist & Group Leader, Early Discovery Biochemistry, Genentech

Drug Substance Dual Sourcing: a CMC Opportunity during Manufacturing Process Validation
Marc C. Constant, PharmD, Senior Director, CMC, NoNoyo Inc., Canada

Transition to Spotlight Presentation Rooms

12:15 Networking Luncheon in Poster and Exhibit Hall
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:55</td>
<td>Chairman's Remarks</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>(2:20) Biomimetic Chemistry of RNAi Therapeutics</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>(2:45) Enhancing Therapeutic Profile of ASOs Using Gap-modifications</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>(3:15) From Stereoparity to Precision Medicine: Optimizing the Properties of</td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td>Oligonucleotide Discovery and Development</td>
<td></td>
</tr>
<tr>
<td>4:15</td>
<td>(4:30) From Rectal Solution to Oral Capsule: Life Cycle Management of</td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>Preclinical and Clinical Development of AST-008, A Toll-like Receptor</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Intracellular Delivery of siRNA Conjugates Leads to Robust and Durable</td>
<td></td>
</tr>
<tr>
<td>5:45</td>
<td>Networking Reception in Poster and Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>
### THURSDAY, MAY 23, 2019

**7:30**  
Registration (Room: Balboa ABC) and Coffee (Room: Seaport Foyer)

**7:45 - 8:15**  
Breakfast Spotlight Presentation (Room: Seaport BC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:20</td>
<td><strong>Chairman's Remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Chairman's Remarks</td>
</tr>
<tr>
<td></td>
<td>G. Susan Srivatsa, Ph.D., President, ElixirPharma</td>
</tr>
<tr>
<td>8:25</td>
<td><strong>Chairman's Remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Trishul Shah, Director, Business Development, North America, PolyPeptide</td>
</tr>
<tr>
<td>8:30</td>
<td><strong>RNAi Delivery: Overcoming a Billion Years of Evolutionary Defenses</strong></td>
</tr>
<tr>
<td></td>
<td>Steven Dowdy, Ph.D., Professor, Cellular and Molecular Medicine, UCSF School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Regulatory Agency Questions and Learnings from Recent Commercial Submissions</td>
</tr>
<tr>
<td></td>
<td>Jennifer Franklin, Director, CMC Regulatory Affairs, Ionis Pharmaceuticals</td>
</tr>
<tr>
<td>8:35</td>
<td><strong>Moving Antibody-Oligonucleotide Conjugates (AOCs) into Development</strong></td>
</tr>
<tr>
<td></td>
<td>Andy Geall, Ph.D., Vice President of Formulations, Analytics and Chemistry, Avidity Biosciences</td>
</tr>
<tr>
<td></td>
<td>Quality Development in European Early Access Approaches (PRIME)</td>
</tr>
<tr>
<td></td>
<td>René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BFAM Federal Institute for Drugs and Medical Devices, Germany</td>
</tr>
<tr>
<td>8:40</td>
<td><strong>Ocular Delivery of siRNA Conjugates: Efficient and Durable Gene Silencing of TTR after Single Intravitrebral Administration of siRNA Conjugates</strong></td>
</tr>
<tr>
<td></td>
<td>Jayaprakash Naic, Ph.D., Associate Director, Research, Alnylam Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Spinraza Regulatory CMC Experiences</td>
</tr>
<tr>
<td></td>
<td>Mia Kistala, Associate Director Regulatory Affairs, Biogen</td>
</tr>
<tr>
<td>8:45</td>
<td><strong>Networking Refreshment Break in Poster and Exhibit Hall</strong></td>
</tr>
<tr>
<td>8:50</td>
<td><strong>Inhibition of Glutathione S-Transferase P (GSTP) for the Treatment of KRAS-Driven NSCLC using a Novel siRNA Lipid Nanoparticle</strong></td>
</tr>
<tr>
<td></td>
<td>Roger Adami, Ph.D., Senior Director Pharmaceutical Sciences, Nitto BioPharma, Inc.</td>
</tr>
<tr>
<td>8:55</td>
<td><strong>Innovation in Oligonucleotide CMC</strong></td>
</tr>
<tr>
<td></td>
<td>FlowFVax: A Synthetic, Adjuvanted Microsphere Vaccine Platform</td>
</tr>
<tr>
<td></td>
<td>Scott Burkholt, Bioinformatics Data Scientist, Flow Pharma</td>
</tr>
<tr>
<td>9:00</td>
<td><strong>Peptide Discovery, Preclinical and Clinical</strong></td>
</tr>
<tr>
<td></td>
<td>mRNA Therapeutics and CRISPR Therapeutics</td>
</tr>
<tr>
<td></td>
<td>mRNA Discovery and Development</td>
</tr>
</tbody>
</table>

### Extra-Hepatic Delivery of Oligonucleotides

<table>
<thead>
<tr>
<th>Room: Seaport A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room: Seaport BC</td>
</tr>
<tr>
<td>Room: Balboa ABC</td>
</tr>
<tr>
<td>Room: La Jolla AB</td>
</tr>
</tbody>
</table>

### Networking Luncheon in Poster and Exhibit Hall

For up-to-date program information and new abstracts, visit: www.TIDSevent.com
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room: Seaport A</th>
<th>Room: Seaport BC</th>
<th>Room: Balboa ABC</th>
<th>Room: La Jolla AB</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:55</td>
<td>Chairman's Remarks</td>
<td>Chairman's Remarks</td>
<td>Chairman's Remarks</td>
<td>Chairman's Remarks</td>
<td>Chairman's Remarks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>Update on the DCR-PHXC and DCR-HBV Clinical Programs and Other Pipeline Progress</td>
<td>Characterization of Critical Quality Attributes of mRNA</td>
<td>Adhesive Dermally Applied Microarray (ADAM): Experience in Osteoporosis, Diabetes and Migraine</td>
<td>Industrial Peptide Purification – Challenges and Concepts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bob Brown, Ph.D., CSO and SVP Research, Dicerna Pharmaceuticals</td>
<td>Penggao Duan, Ph.D., Principal Scientist, Moderna Therapeutics</td>
<td>Mahmoud Ameri, Ph.D., Vice President, Research and Development, Zosano Pharma</td>
<td>Ralf Eisenhuth, Ph.D., Process Manager Technology Transfer and Chromatography, Bachem AG, Switzerland</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>The Oligonucleotide Agent BC 007 Neutralizes Agonistic Autoantibodies Directed Against β1-Adrenoceptors - Data of Clinical Phase 1 Trial</td>
<td>Defining Critical Quality Attributes for RNA Nanoparticle Manufacturing from Extended Characterization</td>
<td>Engineered Amphiphilic Peptides Enable Delivery of Protein and CRISPR Cargoes to Cells</td>
<td>Aggregation of Peptides in Preparative Chromatography</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Annekathrin Haberland, Ph.D., Director Regulatory Affairs, Berlin Cures GmbH, Germany</td>
<td>Heinrich Haas, Ph.D., Vice President, RNA Formulation &amp; Drug Delivery, BioNTech AG, Germany</td>
<td>David Guay, Ph.D., Research Director, Feldan Therapeutics, Canada</td>
<td>Anthony Zidell, Analytical Chemist, Corden Pharma Colorado</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>Anti-FGF2 Aptamer RBM-007 in Phase I/IIa Trials for Wet AMD</td>
<td>Manufacturing and Characterization of mRNA Constructs</td>
<td>Exploiting a Novel Cell Death Mechanism for Selective Killing of Cancer Cells Upregulating Homologous Recombination</td>
<td>High-Throughput Approaches to Column Screening for the Preparative Purification of Peptides</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yusuf Ali, Ph.D., CEO, RIBOMIC USA</td>
<td>Ulrich Blaschke, Ph.D., Vice President for Technical Development, CureVac AG, Germany</td>
<td>Maria Soloveychik, Ph.D., CEO, SyntheX, Inc.</td>
<td>Steven McIntyre, Peptide Process Development Department Manager, Almac Group, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td>Close of Conference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Diamond Sponsor

| Nitto | Avecia |

### Event Partner

| Agilent | Trusted Answers |

### Gold Sponsors

<table>
<thead>
<tr>
<th>aic</th>
<th>BACHEM</th>
<th>ChemGenes Corporation</th>
<th>CORDENPHARMA</th>
<th>LGC</th>
<th>AXOlinx</th>
</tr>
</thead>
<tbody>
<tr>
<td>PolyPeptide</td>
<td>RIBOBIO</td>
<td>TriLink</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Silver Sponsors

| Aj | BIO-PHARMA SERVICES | GYROS PROTEIN Technologies | ST PHARM | ThermoFisher SCIENTIFIC |

### Bronze Sponsors

| Avanti | Exelead | Intertek | Nippon Biotech | NAGASE | SUMITOMO CHEMICAL |

### Associate Sponsors

| BIOSPRING | Intellia THERAPEUTICS | BTA | MSTN | ThermoFisher SCIENTIFIC | TriLink |

### Registration Sponsor

| PYRAMID Laboratories, Inc. | PolyPeptide GROUP |

### Bag Sponsor

| PolyPeptide GROUP |

### Lanyard Sponsor

| LGC | AXOlinx |

### Reception Sponsors

| BACHEM | RIBOBIO | ThermoFisher SCIENTIFIC | PolyOrg, Inc. | ST PHARM |

### Lunch Sponsor

| PolyOrg, Inc. | ST PHARM |

### Notepad and Pen Sponsor

| PolyOrg, Inc. | ST PHARM |

### WiFi Sponsor

| API |

---

For more information on how you can connect with key buyers at TiDES 2019, contact:

Michael Moriarty, 646-895-7412 | Michael.Moriarty@KNect365.com
### Ways to Register

**Easiest:** [www.TIDESevent.com](http://www.TIDESevent.com)

**Call:** 888-670-8200 or +1.941.554.3500

**Email:** register@KNect365.com

### Industry Rates

<table>
<thead>
<tr>
<th>Service</th>
<th>Standard Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Day Main Conference Access (Tues - Thurs)</td>
<td>$2,799</td>
</tr>
<tr>
<td>3 Day Main Conference Access: Group 4+ Rate (Tues - Thurs)</td>
<td>$2,599 per person</td>
</tr>
</tbody>
</table>

### Academic/Government Rates*

<table>
<thead>
<tr>
<th>Service</th>
<th>Standard Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Day Main Conference Access (Tues - Thurs)</td>
<td>$899</td>
</tr>
<tr>
<td>3 Day Main Conference Access: Group 4+ Rate (Tues - Thurs)</td>
<td>$749 per person</td>
</tr>
</tbody>
</table>

### Additional Options

<table>
<thead>
<tr>
<th>Service</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry Add on Workshop</td>
<td>$699</td>
</tr>
<tr>
<td>Acad/Govt Add on Workshop</td>
<td>$250</td>
</tr>
<tr>
<td>Poster Fee for Industry</td>
<td>$150</td>
</tr>
<tr>
<td>Poster Fee for Academic/Govt</td>
<td>$0</td>
</tr>
</tbody>
</table>

*Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.

Any registered attendee may add a full-day workshop pass to their main conference package. A workshop pass provides access to one (1) morning and (1) afternoon workshop. All workshops are held on Monday, May 20, 2019.

### Conference Venue

Manchester Grand Hyatt
1 Market Pl, San Diego, CA 92101
Take Advantage of Our Discounted Hotel Rooms

### Send Your Team to TIDES and Save

Register your team of 4+ to receive an additional $200 savings/person off the current industry rate. Secure your team's place today by contacting Jess Purnell at jessica.purnell@knect365.com +44 (20) 7551 952

### Present a Scientific Poster at TIDES 2019

Share your company's latest research by presenting a poster at TIDES 2019. All posters are displayed inside the exhibit hall throughout the meeting. Poster presentation space is now at capacity. We will no longer be able to accept any additional poster requests.